化疗联合调强放疗治疗食管癌的疗效及不良反应评价

Efficacy and adverse reactions of chemotherapy combined with intensitymodulated radiation therapy for esophageal cancer

目的探讨化疗联合调强放疗在食管癌治疗中的应用价值。方法按照治疗方案的不同将120例食管癌患者分为对照组和观察组,各60例。全部患者均接受5-氟尿嘧啶+顺铂化疗,对照组患者同时接受常规放疗,观察组患者同时接受调强放疗。比较两组患者的近期疗效。结果观察组患者的治疗总有效率为88.33%(53/60),明显高于对照组患者的58.33%(35/60),差异有统计学意义(P﹤0.01)。两组患者均发生了放疗相关不良反应,包括放射性食管炎、放射性肺炎、骨髓抑制;观察组患者的放疗相关不良反应的发生率均明显低于对照组,差异均有统计学意义(P﹤0.01)。结论食管癌患者在接受化疗的同时接受调强放疗,既可以提高近期疗效,又可以减少放射不良反应的发生,治疗安全性较高。

Objective To assess the value of applying the combined regimen of chemotherapy and intensity-modulated radiation therapy(IMRT)in the treatment of esophageal cancer.Method According to the different treatment plan,the analysis included 120 patients with esophageal cancer as control group and study group,with 60 cases in each.All patients received 5-fluorouracil+cisplatin chemotherapy,and the control group received additional conventional radiotherapy,in contrast,the add-on IMRT was administered in study group.The short-term efficacy of the two groups was compared.Result The response rate in study group was 88.33%(53/60),which was significantly higher than the 58.33%(35/60)in control group,and the difference was statistically significant(P<0.01).Patients in both groups developed radiationinduced adverse reactions,including esophagitis,pneumonia,and bone marrow suppression,with lower incidence in study group than in control group,the differences were statistically significant(P<0.01).Conclusion Intensity-modulated radiotherapy on the basis of chemotherapy not only increases the short-term efficacy,but also reduces the incidence of radiation-induced adverse reactions,with acceptable safety.